KRYS

Krystal Biotech Inc.

Price

$325.95

return (12m)

77.77%

p/e

39.86

p/bv

7.08

DIVIDEND YIELD

0.00%

KRYS price

Krystal Biotech

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment KRYS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-9.31%

3 months

-12.81%

1 year

77.77%

2 years

85.27%

5 years

503.28%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals KRYS

Valuation

P/E

39.86

Sector -3.46

Industry -3.46

P/BV

7.08

Sector 1.94

Industry 1.94

P/Revenue (PSR)

21.85

Sector 1.96

Industry 1.96

EV/EBITDA

146.36

Sector -216.42

Industry -216.42

EV/EBIT

150.29

Sector -46.11

Industry -46.11

P/EBITDA

47.09

Sector -21.02

Industry -21.02

P/EBIT

48.67

Sector -27.60

Industry -27.60

P/Total Assets

6.41

Sector 1.14

Industry 1.14

P/Net Current Assets

10.48

Sector -10.24

Industry -10.24

P/Working Capital

10.32

Sector -162.19

Industry -162.19

EPS

8.18

Sector -1.78

Industry -1.78

BVPS

46.03

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

94.64%

Sector 41.35%

Industry 41.35%

EBITDA Margin

50.31%

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

49.00%

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

44.89%

Sector -35.47%

Industry -35.47%

Net Profit Margins

54.82%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.08

Sector 0.03

Industry 0.03

Profitability

ROE

17.77%

Sector -57.40%

Industry -57.40%

ROA

16.09%

Sector -59.43%

Industry -59.43%

ROIC

38.60%

Sector -2,370.21%

Industry -2,370.21%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

8.32

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-14.10

Sector -21.98

Industry -21.98

Net Debt / EBIT

-14.48

Sector -8.44

Industry -8.44

Net Debt / Equity

-0.62

Sector -33,112.99

Industry -33,112.99

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.91

Sector 0.46

Industry 0.46

Liabilities/Assets

0.09

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals KRYS

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Krystal Biotech ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$325.95

Fair Value

$92.04

Upside

-71.76%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KRYS Krystal Biotech Inc.	$325.95	81.48%	0.00%	39.86	7.08	17.77%	54.82%
PFE Pfizer Inc.	$27.48	8.11%	6.26%	36.14	1.83	5.07%	6.80%
ABBV AbbVie Inc.	$259.97	9.77%	2.63%	72.88	-77.57	-106.44%	9.81%
NVO Novo Nordisk A/S	$37.23	-33.47%	4.98%	9.10	4.83	53.11%	35.32%
MRK Merck & Co. Inc.	$143.18	65.09%	2.36%	110.80	8.37	7.56%	4.77%
AZN AstraZeneca PLC	$156.59	-4.79%	2.06%	18.71	4.82	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$60.33	34.59%	4.20%	13.14	5.46	41.59%	18.87%
ZTS Zoetis Inc.	$69.46	-51.82%	3.01%	11.00	9.21	83.77%	27.69%
AMGN Amgen Inc.	$402.15	38.44%	2.47%	24.84	18.58	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$729.88	22.13%	0.51%	17.33	2.37	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$108.98	45.42%	0.00%	30.90	89.03	288.13%	24.86%
MCK McKesson Corporation	$888.29	16.56%	0.38%	22.96	-27.29	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$501.27	24.01%	0.00%	28.87	6.28	21.76%	35.00%
CAH Cardinal Health Inc.	$226.17	45.05%	0.91%	30.94	-19.47	-62.92%	0.67%
ARGX argenx SE	$914.13	19.13%	0.00%	20.47	5.36	26.20%	25.70%
HRMY Harmony Biosciences Holdings Inc.	$39.41	46.40%	0.00%	12.60	2.28	18.14%	18.88%
BIIB Biogen Inc.	$220.34	42.87%	0.00%	38.99	1.73	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KRYS - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Krystal Biotech

Krystal Biotech Inc.

Average Investor10 user rating

4.0 (3 people)

United States

11 years

Founded: 2015

2017

Time since IPO - 9 years

75

Employees

Krystal Biotech Inc. (United States) is listed on the Nasdaq and has a market capitalization of $9.62 billion, with shareholders equity totaling $1.36 billion.

The company employs approximately 75 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Krystal Biotech Inc. reported $440.48 million in revenue, generating net income of $241.47 million.

Key financial metrics include a P/E ratio of 39.86, a price-to-book (P/B) ratio of 7.08, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker KRYS.

Market cap

$9.62 billion

Net worth

$1.36 billion

$1,359,126,000.00

Assets

$1.50 billion

$1,500,648,000.00

Total Shares Outstanding

29.53 million

29,529,000

Average Daily Trading Volume

$295.17 Thousand

$295,174.10

Sector

Health Care

Industry

Biotechnology

KRYS

KRYS revenue and profits

Financial Results KRYS

DRAG THE FRAME TO SEE MORE DATA

KRYS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$888.29 20,83% (12M)

P/E

22.96

0.38%

ROE

-118.84%

P/BV

-27.29

CAH - Cardinal Health

$226.17 47,96% (12M)

P/E

30.94

0.91%

ROE

-62.92%

P/BV

-19.47

ABBV - AbbVie

$259.97 14,69% (12M)

P/E

72.88

2.63%

ROE

-106.44%

P/BV

-77.57

MRK - Merck & Co.

$143.18 65,85% (12M)

P/E

110.80

2.36%

ROE

7.56%

P/BV

8.37

AZN - AstraZeneca

$156.59 --6,84% (12M)

P/E

18.71

2.06%

ROE

25.77%

P/BV

4.82

PFE - Pfizer

$27.48 7,47% (12M)

P/E

36.14

6.26%

ROE

5.07%

P/BV

1.83

BMY - Bristol-Myers Squibb

$60.33 39,02% (12M)

P/E

13.14

4.20%

ROE

41.59%

P/BV

5.46

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$888.29 20,83% (12 M)

P/L

22.96

0.38%

ROE

-118.84%

P/VP

-27.29

CAH - Cardinal Health

$226.17 47,96% (12 M)

P/L

30.94

0.91%

ROE

-62.92%

P/VP

-19.47

ABBV - AbbVie

$259.97 14,69% (12 M)

P/L

72.88

2.63%

ROE

-106.44%

P/VP

-77.57

MRK - Merck & Co.

$143.18 65,85% (12 M)

P/L

110.80

2.36%

ROE

7.56%

P/VP

8.37

AZN - AstraZeneca

$156.59 --6,84% (12 M)

P/L

18.71

2.06%

ROE

25.77%

P/VP

4.82

PFE - Pfizer

$27.48 7,47% (12 M)

P/L

36.14

6.26%

ROE

5.07%

P/VP

1.83

BMY - Bristol-Myers Squibb

$60.33 39,02% (12 M)

P/L

13.14

4.20%

ROE

41.59%

P/VP

5.46

Frequently Asked Questions

What is the price of Krystal Biotech (KRYS) today?

The current price of Krystal Biotech (KRYS) is $325.95. The stock began the year trading around $246.54 and is currently priced at $325.95. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Krystal Biotech (KRYS) pay dividends?

Krystal Biotech (KRYS) did not pay dividends over the past year.

Is Krystal Biotech (KRYS) a good investment?

Krystal Biotech (KRYS) is currently trading at $325.95 with a P/E ratio of 39.86. This represents a 8,627% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 77.77%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Krystal Biotech (KRYS) stock?

You can buy Krystal Biotech (KRYS) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol KRYS and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Krystal Biotech (KRYS) yield today?

Over the past month, Krystal Biotech (KRYS) has returned -9.31% — 77.77% over the past year, and 503.28% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Krystal Biotech (KRYS) today at the current price of $325.95 your total investment would be $32,595.00.

Based on historical performance, the investment would have grown to approximately:

$57,944.13 after 1 year
$196,639.12 after 5 years
$32,595.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KRYS

Krystal Biotech Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KRYS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING KRYS WITH OTHER STOCK

ABOUT Krystal Biotech

Krystal Biotech Inc.

United States

11 years

2017

75

PROFIT X PRICE KRYS

Financial Results KRYS

KRYS cash flow

Asset, Revenue and Profit Growth - KRYS

KRYS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions